全文获取类型
收费全文 | 519篇 |
免费 | 43篇 |
出版年
2021年 | 7篇 |
2018年 | 11篇 |
2017年 | 9篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 6篇 |
2013年 | 18篇 |
2012年 | 21篇 |
2011年 | 27篇 |
2010年 | 14篇 |
2009年 | 17篇 |
2008年 | 15篇 |
2007年 | 22篇 |
2006年 | 23篇 |
2005年 | 25篇 |
2004年 | 22篇 |
2003年 | 10篇 |
2002年 | 21篇 |
2001年 | 14篇 |
2000年 | 16篇 |
1999年 | 13篇 |
1998年 | 8篇 |
1997年 | 15篇 |
1996年 | 7篇 |
1994年 | 8篇 |
1992年 | 4篇 |
1991年 | 10篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1986年 | 8篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 10篇 |
1980年 | 3篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1975年 | 9篇 |
1974年 | 4篇 |
1973年 | 7篇 |
1972年 | 7篇 |
1971年 | 9篇 |
1970年 | 6篇 |
1969年 | 8篇 |
1968年 | 3篇 |
1967年 | 11篇 |
1966年 | 6篇 |
1961年 | 3篇 |
排序方式: 共有562条查询结果,搜索用时 15 毫秒
561.
Cyclins are indispensable elements of the cell cycle and derangement of their function can lead to cancer formation. Recent studies have also revealed more mechanisms through which cyclins can express their oncogenic potential. This review focuses on the aberrant expression of G1/S cyclins and especially cyclin D and cyclin E; the pathways through which they lead to tumour formation and their involvement in different types of cancer. These elements indicate the mechanisms that could act as targets for cancer therapy. 相似文献
562.
Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes 总被引:40,自引:0,他引:40
D T Golenbock R Y Hampton N Qureshi K Takayama C R Raetz 《The Journal of biological chemistry》1991,266(29):19490-19498
Lipopolysaccharide (LPS) endotoxin is implicated as the bacterial product responsible for the clinical syndrome of Gram-negative septicemia. Although the lipid A domain of LPS appears to be responsible for the toxicity of endotoxin, lipid A from the photosynthetic bacterium Rhodobacter sphaeroides (RSLA) and a disaccharide precursor of lipid A from enteric bacteria, termed lipid IVA, have little activity on human cells. Using the human promonomyelocytic cell line THP-1 and human monocytic cells, we now show that both lipid IVA and RSLA are antagonists of LPS. Complete, apparently competitive, inhibition of LPS activity is possible at a 10-100-fold excess of antagonist, as judged by measuring the release of cytokines and prostaglandin E2. Both antagonists prevent monocyte stimulation by endotoxin extracted from a variety of Gram-negative bacteria. Cells pretreated with either inhibitor and subsequently washed still show attenuated responses to LPS. Stimulation of monocytes by whole Gram-negative bacteria is also antagonized in a dose-dependent manner. Lipid X has no inhibitory effect in the same dose range as lipid IVA and RSLA. These findings rule out LPS sequestration as the explanation for the observed antagonism. Neither inhibitor alters monocyte stimulation by phorbol 12-myristate 13-acetate, Staphylococcus aureus, or purified protein derivative, demonstrating specificity for LPS. Although RSLA appears to inhibit LPS when tested with macrophages from both humans and mice, lipid IVA had the unique ability to act as an LPS antagonist with human-derived cells but to exhibit LPS-like effects with murine-derived cells. Like LPS, lipid IVA stimulated the release of both tumor necrosis factor alpha and arachidonic acid from murine-derived RAW 264.7 macrophage tumor cells. The range of concentrations necessary for lipid IVA to induce LPS-like effects in murine cells was similar to that necessary to antagonize the actions of LPS in human monocytes. The agonist activities of lipid IVA were completely inhibitable by RSLA. This unique species-dependent pharmacology observed with lipid IVA may reflect differences between human and murine LPS receptors. RSLA and lipid IVA may be useful in defining the role of LPS in Gram-negative bacterial infections and may prove to be prototypical therapeutic agents for the treatment of Gram-negative septicemia. 相似文献